Symbol | Exchange | Currency |
|---|
Pre-Open Stock Movers:Netflix (NASDAQ:NFLX) 28% LOWER; Q1 global streaming subscribers fell 200k versus an expected gain of 2.5 million. Q1 EPS was $3.53, versus the consensus of...
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Consumer Goods, Technology and Healthcare sectors led shares higher while losses in the Oil & Gas,...
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Buy | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.45 | 0.52 | 0.45 | -0.05 | -10.21% | 972.13K | NASDAQ | |||
| 241.83 | 243.89 | 235.41 | +1.69 | +0.70% | 531.55K | NYSE | |||
| 76.47 | 78.91 | 75.48 | -1.52 | -1.95% | 104.55M | NASDAQ | |||
| 15.33 | 15.55 | 15.23 | -0.23 | -1.48% | 92.51K | NASDAQ | |||
| 52.64 | 53.05 | 51.89 | -0.33 | -0.62% | 2.09M | NYSE | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 143.79 | 144.44 | 141.23 | +1.59 | +1.12% | 7.34M | NYSE | |||
| 56.58 | 57.36 | 55.85 | -0.59 | -1.03% | 4.24M | NASDAQ | |||
| 41.99 | 42.00 | 41.46 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 13.20 | 13.46 | 12.54 | +0.01 | +0.08% | 376.47K | NASDAQ | |||
| 35.69 | 35.73 | 34.33 | -0.22 | -0.61% | 3.31M | NYSE | |||
| 4.91 | 5.08 | 4.85 | -0.24 | -4.66% | 717.12K | NASDAQ | |||
| 44.33 | 44.71 | 43.28 | -0.20 | -0.45% | 326.56K | NASDAQ | |||
| 1.38 | 1.44 | 1.35 | -0.050 | -3.50% | 4.88M | NASDAQ | |||
| 46.99 | 47.38 | 45.00 | -0.18 | -0.38% | 1.77M | NASDAQ |